Sir: Risperidone, like clozapine, has been associated with the induction or exacerbation of obsessive-compulsive symptoms, which has been hypothesised to be related to its 5-HT, antagonistic action (Eales & Layeni, 1994; Kopala & Honer, 1994; Remington & Adams, 1994; Alzaid &Jones, 1997) . It could also be speculated that risperidone's antiserotonergic properties could lead to obsessive and depressive symptoms, as the following case demonstrates.
A 29-year-old man with ICD-10 paranoid schizophrenia was placed on risperidone monotherapy (4 mg/day). Within one month he developed ICD-10 major depression and obsessions (repetitive cursing thoughts with religious and sexual content). The depression interfered seriously with everyday activities. After starting fluoxetine (20 mg/day) his obsessions resolved within two weeks and the depression resolved within three weeks. Over the fourth week he developed akathisia, and fluoxetine was discontinued. The akathisia resolved but within the next four weeks the depressive and obsessive symptoms relapsed. Risperidone was decreased to 2 rnglday but the symptoms did not resolve (although he experienced a reduction in frequency and intensity) and the treatment was stopped. The patient was put on pirnozide without re-emergence of these symptoms. He had no prior history of obsessive or depressive symptoms. There was no evidence of an organic aetiology.
Unlike many traditional antipsychotics, risperidone is a more potent antagonist of serotonin (5-HT,) than of dopamine (D,) receptors and this action has been postulated to contribute to its atypical effects and to produce or unmask obsessivecompulsive symptoms (Eales & Layeni, 1994; Kopala & Honer, 1994; Remington & Adams, 1994; Alzaid & Jones, 1997 ). There have not been any reported cases of depression or combination of depressive and obsessive symptoms in the literature up to now. The emergence of these symp toms during the course of treatment with risperidone, the positive effects of fluoxetine, the re-emergence of these symptoms after discontinuation of fluoxetine and their resolution when risperidone was discontinued, together provide strong evidence that risperidone was a causative factor.
The combination of a serotonin recep tor blocker (risperidone) and a serotonin reuptake inhibitor (fluoxetine) appears to be antagonistic. It is well known that fluoxetine is useful for the treatment of depression and obsessive-compulsive symptoms. Our data suggest that serotonin blockade may underlie the development of depressive and obsessive symptoms in the course of risperidone treatment. The success of fluoxetine in treating these symptoms supports this conclusion further, as do reports involving obsessive symptoms managed with fluvoxamine (Remington & Adams, 1994) or with discontinuation of risperidone (Kopal & Honer, 1994) .
However, fluoxetine caused akathisia, although it did not exacerbate the psychotic symptoms in this patient. Clinicians need to be aware of fluoxetine's potential to activate psychotic processes or cause extrapyramidal side-effects (Lindenmayer et a1, 1990) .
These topics are complicated because of the different actions of risperidone and fluoxetine on different parts of the central nervous system and on different types of receptors (5-HT,, 5-HT,, D,, D,, etc.) (Eales & Layeni, 1994; Kopala & Honer, 1994) , the interactions of these two agents, as well as antidepressant effects of risperidone (Dwight et a1, 1994) . a1 (1991) where remission begins when a patient does not have any of the Research Diagnostic Criteria (RDC) symptoms of major depression. If remission is maintained for eight weeks, the patient is considered recovered. Return of symptoms of major/minor depression during the eight weeks after losing symptoms heralds a relapse, whereas if this occurs after an eight-week symptom-free interval the individual is considered to have had a recurrence. The pivotal importance given to a two-month symptom-free interval in differentiating a relapse from a recovery is embodied in DSM-N (American Psychiatric Association, 1994) as well, whereas ICD-10 (World Health Organization, 1992) skirts the issue by using the phrase "several months" rather than commit itself to a definite time frame. However, inadequate to define complete recovery from an episode of depression, and warrants fresh attempts to achieve consensus definitions for remission, recovery, relapse and recurrence in major depressive disorder. depressants is usually recommended for four to six months after full recovery. Using the recommendation of four months of continuation treatment (Depression Guideline Panel, 1993) , Ramana et a1 (1999) observed grief that 31 of 77 subjects who 'recovered' from and depression had a return of symptoms in the continuation phase of antidepressant treatment. This implies that they had not actually recovered from the underlying pathophysiology of the episode but had only achieved symptomatic recovery. They would be then classified as having had a relapse rather than a recurrence, as would be the case if Frank et al's definition (1991) were followed. A recent randomised controlled trial by Reirnherr et a1 (1998) on the optimal length of continuation therapy in depression addresses this crucial issue in the research and treatment of depressive disorders. Based on their trial, which involved prospective transfer to placebo at multiple points, the authors recommend an additional 26 weeks of fluoxetine after remission to prevent re-emergence of depressive symptoms, thereby proposing that the end of this period defines recovery from the underlying pathophysiology of an episode of depression. This suggests that two months of remission, as proposed by Frank et a1 (1991) and in DSM-N, is Sir: We were interested in Prigerson et UPS (1999) consensus criteria for traumatic grief. There were some concepts in the distinction from post-traumatic stress disorder (PTSD) with which we would take issue. Criterion B, in particular, appears to overlap significantly with PTSD. Avoidance of reminders is one of the key criteria in DSM-N PTSD (American Psychiatric Association, 1994), as well as emotional numbing. In fact, most of Prigerson et UPS criterion B can be seen in PTSD. We also feel concerned about the two months of symptoms which the authors have used as a time scale, since clinically this overlaps with normal grief. The distinctness of this diagnosis must, therefore, be questioned. No mention is made of the adjustment reaction and the distinction from this, and in ICD-10 (World Health Organization, 1992) many atypical grief reactions are put in this section.
The authors had a 42% response rate in their study which was predominantly female, of a mean age of 61 years and Caucasian. This undermines the generalisability of the study. Furthermore, in our clinical work on PTSD, avoidance symptoms often delay presentation and this might be significant in the rest of their sample.
Post-traumatic stress disorder is a condition with a 50-95% comorbidity (Green et al, 1992) and it is inherently problematic to sort out comorbidity (Yehuda & Mcfarlane, 1995) . Further, a recent epidemiological study found a risk of developing PTSD of 31 % following unexpected death of a loved one (Breslau et al, 1998) . A recent paper reinforced the link between grief and PTSD, showing that they appear to share common predictors (Sprang & McNeil, 1998) . If this is the case, then perhaps PTSD and traumatic grief syndrome represent a spectrum of severity, or are potential alternatives, or are potentially comorbid. We also wonder whether including this as a sub-specifier in PTSD might be a better place for it, rather than as a distinct diagnosis. The work which the authors have undertaken is preliminary but we feel may assist in the better definition of PTSD and traumatic grief. ~uthort'reply: We appreciate the attention Dr Fox and colleagues have drawn to the distinction between the criteria for PTSD and those we propose for traumatic grief. As stated in our article: "we acknowledge the reaction to be a stress response syndrome
